Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.74 |
| ▸ | CA2 | P00918 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086764 | 1.00 | CA1 (0.74) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL11793140 | 0.90 | CA1 (0.85) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL540915 | 0.90 | CA1 (0.85) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL7501950 | 0.90 | CA1 (0.81) | CA1CA2KMT2AALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL5797806 | 0.88 | CA1 (0.79) | CA1CA2KMT2AALDH1A1MAPK1 | |
| SCHEMBL28352311 | 0.88 | CA1 (0.59) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL19603195 | 0.85 | CA1 (0.76) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL28352310 | 0.84 | CA1 (0.55) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL7834458 | 0.84 | HTR6 (0.65) | CA1CA2HTTCA9KMT2A | |
| SCHEMBL153131 | 0.83 | CA1 (1.00) | CA1CA2HTTCA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084744-A | Aloe-emodin derivative and preparation method and application thereof | 广西民族大学 | 2024-05-28 | — | — | CN | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055233-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| CN-1110489-C | Benzisoelenazolone sulfamide derivative, its preparing process and its application in preparing medicines | INST OF PHARMACOLOGY CHINESE A (CN) | 2003-06-04 | — | — | CN | disclosed |
| CN-1253135-A | Benzisoelenazolone sulfamide derivative, its preparing process and its application in preparing medicines | INST OF PHARMACOLOGY CHINESE A (CN) | 2000-05-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | CA1 3919/4885CA2 4239/4885HTT 4222/4885 |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | ERBB3, ERBB2, AXL | CA1 3473/4885CA2 1825/4885HTT 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.